Skip to main content
Premium Trial:

Request an Annual Quote

Meanwhile, the Pricing Folks at Nature and Science Rejoice

Peter Suber, who spends his days thinking about open access issues, posted this entry on his blog -- it's an excerpt from a press release issued by Yale explaining its libraries' decision to stop supporting BioMed Central's Open Access publishing effort. The problem was financial: the libraries paid for the author page charges, which allowed those papers to be freely available online. The first year's charges came in under $5,000 but soared to more than $31,000 in 2006, the second year. This year looks to continue that trend, the libraries said, adding that the business model was "unsustainable" and "failed to provide a viable long-term revenue base built upon logical and scalable options," according to the press release.

Looks like it's back to the drawing board for at least some open-access proponents.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.